PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

This study — called PACCELIO — is testing whether a specialized PET scan (FDG-PET) can be used to guide smaller, more targeted radiation treatment fields combined with immunotherapy and chemotherapy for people with locally advanced, inoperable non-small cell lung cancer (NSCLC). The goal is to reduce radiation side effects while maintaining effectiveness. **You may be eligible if...** - You are 18 years or older - You have been confirmed to have inoperable, locally advanced (Stage III) non-small cell lung cancer (NSCLC) - Your tumor has at least 1% PD-L1 expression (a marker that helps predict response to immunotherapy) - You are in good general health (ECOG 0–1) - You are fit to receive combined chemotherapy, radiation, and immunotherapy - A recent FDG-PET scan has been done within 21 days before starting treatment - Your lung function tests are within acceptable range **You may NOT be eligible if...** - You have already received systemic treatment for this lung cancer - You have serious autoimmune conditions - You have significant other illnesses that make combination treatment unsafe - Your lung function is too low to tolerate treatment Talk to your doctor to see if this trial is right for you.